Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radiprodil in GRIN-Related Neurodevelopmental Disorder (Phase 3 randomized and open-label extension)
jRCT2041260070Phase 3Recruiting
- Sponsor
- GRIN Therapeutics, Inc.
- Start
- Aug 2026
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of radiprodil in GRIN-related disorder (5 arms), sponsored by GRIN Therapeutics, Inc. Primary endpoints: Primary – CMS frequency during Maintenance Period (Qualifying Seizures cohort), Primary – Safety (Without Qualifying Seizures Auxiliary cohort) and 1 more. Started Aug 2026; status: recruiting.
02
Drugs
radiprodil
03
Conditions
GRIN-related disorder
Beyond the preview
Go deeper on jRCT2041260070.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041260070.